Results 131 to 140 of about 69,810 (276)
Journal of Applied Toxicology, EarlyView.ABSTRACT Diisononyl phthalate (DINP) is a high molecular weight phthalate and high production volume chemical. DINP's carcinogenic potential has been investigated in four rodent bioassays, with liver tumors observed in three of the studies. Authoritative assessments have hypothesized that DINP acts through the peroxisome proliferator‐activated receptor
Amanda N. Buerger +3 more
wiley +1 more source
Journal of Pediatric Gastroenterology and Nutrition, EarlyView.Abstract Objectives Shwachman‐Diamond syndrome (SDS) is an inherited bone marrow failure disorder, and its hepatic phenotype is poorly defined. Our objective was to systematically characterize the prevalence, features, and outcomes of liver injury in a multicenter SDS cohort. Methods Retrospective registry study of 171 patients with biallelic Shwachman‐
Jane Koo +16 more
wiley +1 more source
The Kaohsiung Journal of Medical Sciences, EarlyView.ABSTRACT Metabolic dysfunction‐associated steatotic liver disease (MASLD) has emerged as the most prevalent chronic liver disease worldwide, closely linked to the global rising incidence of obesity and metabolic syndrome. This review synthesizes current evidence on the pathogenesis, gut–liver axis, and multidisciplinary management of MASLD within the ...
Beom Kyung Kim
wiley +1 more source
Melatonin Promotes Improvement in Serum Lipid Levels and Liver Histopathology in Hyperlipidemic Rats
Lipids, EarlyView.ABSTRACT Hyperlipidemia or dyslipidemia is the term used for the increase in lipid levels in blood plasma, usually occurring due to a high‐fat diet associated with a sedentary lifestyle. The increase in lipid levels can cause fatty infiltration in the liver known as hepatic steatosis, which can lead to inflammation, fibrosis, and necrosis consecutively.
Ana Cláudia Carvalho de Sousa +9 more
wiley +1 more source
From HBV to MASLD Cirrhosis: Mechanistic Insights and Therapeutic Strategies
Portal Hypertension &Cirrhosis, EarlyView.This review examines the epidemiological shift from hepatitis B virus (HBV) to metabolic dysfunction‐associated steatotic liver disease (MASLD) as the leading cause of cirrhosis globally. It highlights the distinct pathogenic mechanisms between HBV and MASLD cirrhosis and discusses evolving diagnostic tools and therapeutic strategies tailored to the ...
Hanqi Yu +5 more
wiley +1 more source
Magnetic Resonance imaging (MRI) in detection of _Bifidobacterium longum_ and _Clostridium novyi-NT_ labeled with superparamagnetic iron oxide (SPIO) nanoparticle [PDF]
, 2009 *Purpose:* To investigate the MR imaging of _Bifidobacterium longum_ and _Clostridium novyi-NT_ labeling with superparamagnetic iron oxide (SPIO) nanoparticles. *Materials and methods:* Tubes containing _B. longum_-SPIO, Free-SPIO, _B.
Dan Li +4 more
core +1 more source
Uric Acid in Metabolic Dysfunction‐Associated Steatotic Liver Disease
Portal Hypertension &Cirrhosis, EarlyView.MASLD is the most prevalent chronic liver disease worldwide, yet effective pharmacological treatments remain limited. Hyperuricemia is now recognized as a key driver of hepatic steatosis, inflammation, and fibrosis, with elevated serum uric acid levels independently predicting hepatocellular carcinoma and liver‐related mortality.
Rong Wang +5 more
wiley +1 more source
Endothelin and other mediators in the pathophysiology of portal hypertension [PDF]
, 1998 Bilzer, Manfred +2 more
core +1 more source
Phytochemicals in MASLD: A Focused Review of Gut Microbiome‐Linked Mechanisms
Phytotherapy Research, EarlyView.ABSTRACT Metabolic dysfunction‐associated steatotic liver disease (MASLD) has emerged as a major global health burden, yet effective pharmacological options remain limited. Recent advances highlight the gut microbiome as a key modulator of liver metabolism, inflammation, and fibrosis, making it a promising therapeutic target.
Jeong In Seo, Su Min Kim, Hye Hyun Yoo
wiley +1 more source